DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on July 31, 2008; DOI: 10.1124/dmd.108.021816


0090-9556/08/3611-2287-2291$20.00
DMD 36:2287-2291, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.021816v1
36/11/2287    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyazaki, M.
Right arrow Articles by Yamamoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyazaki, M.
Right arrow Articles by Yamamoto, K.

Defective Activity of Recombinant Cytochromes P450 3A4.2 and 3A4.16 in Oxidation of Midazolam, Nifedipine, and Testosterone

Mitsue Miyazaki, Katsunori Nakamura, Yukiyoshi Fujita, F. Peter Guengerich, Ryuya Horiuchi, and Koujirou Yamamoto

Department of Clinical Pharmacology, Gunma University Graduate School of Medicine (M.M., K.N., R.H., K.Y.) and Department of Pharmacy, Gunma University Hospital (Y.F., R.H., K.Y.), Gunma, Japan; and Department of Biochemistry and Center in Molecular Toxicology (F.P.G.), Vanderbilt University School of Medicine, Nashville, Tennessee

Cytochrome P4503A4 (CYP3A4) is the most abundant cytochrome P450 in adult human liver and small intestine and oxidizes numerous clinically, physiologically, and toxicologically important compounds. The metabolic activity of CYP3A4 in patients varies at least 10-fold in vivo, and CYP3A4 genetic variants are considered one of the causes of individual differences. The cDNAs for the CYP3A4*2 (S222P), *7 (G56D), *16 (T185S), and *18 (L293P) mutant alleles, found in high frequencies in Caucasians or Asians, were constructed by site-directed mutagenesis and expressed in an Escherichia coli expression system. Midazolam (MDZ), testosterone (TST), and nifedipine (NIF) were used to assess the catalytic activities of the CYP3A4 wild type (CYP3A4.1) and its variants. The catalytic activities of CYP3A4.2 and CYP3A4.16 were reduced (lower Vmax and increased Km relative to CYP3A4.1) for all substrates. The CYP3A4.7 showed lower Vmax values for MDZ and NIF (60 and 84%, respectively) and a higher Km (2-fold) for TST but not for MDZ or NIF. Although CYP3A4.18 showed low Vmax values for MDZ, NIF, and TST (88, 72, and 80% of CYP3A4.1, respectively), no significant differences were identified in the ratio Vmax/Km. In summary, CYP3A4.2 and CYP3A4.16 exhibited significantly lower activity for MDZ, TST, and NIF oxidations than CYP3A4.1. Therefore, drugs metabolized by only CYP3A should be carefully administered to patients with these alleles.


Address correspondence to: Dr. Katsunori Nakamura, Department of Clinical Pharmacology, Gunma University Graduate School of Medicine, Showa-machi 3-39-22, Maebashi 371-8511, Gunma, Japan. E-mail: nkatsu{at}showa.gunma-u.ac.jp




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, P. Y. Takahashi, P. D. Roebuck, J. N. Bailey, D. M. Keenan, and J. D. Veldhuis
Testosterone's Short-Term Positive Effect on Luteinizing-Hormone Secretory-Burst Mass and Its Negative Effect on Secretory-Burst Frequency Are Attenuated in Middle-Aged Men
J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3978 - 3986.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.